

Perspectives in Psychopharmacology

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

2020

- Anderson KN, Lind JN, Simeone RM, et al: Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. *JAMA Psychiatry* 2020; e202453
- Cuijpers P, Noma H, Karyotaki E, et al: A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry* 2020; 19:92–107
- Fagiolini A, Alcalá JÁ, Aubel T, et al: Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. *Ann Gen Psychiatry* 2020; 19:55
- Faraone SV, Rostain AL, Montano CB, et al: Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. *J Am Acad Child Adolesc Psychiatry* 2020; 59:100–112
- Forester BP, Parikh SV, Weisenbach S, et al: Combinatorial pharmacogenomic testing improves outcomes for older adults with depression. *Am J Geriatr Psychiatry* 2020; 28:933–945**
- Gerhard T, Stroup TS, Correll CU, et al: Mortality risk of antipsychotic augmentation for adult depression. *PLoS One* 2020; 15:e0239206**
- Jiang WL, Cai DB, Yin F, et al: Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Transl Psychiatry* 2020; 10:117
- Kim N, McCarthy DE, Piper ME, et al: Comparative effects of varenicline or combination nicotine replacement therapy versus patch monotherapy on candidate mediators of early abstinence in a smoking cessation attempt. *Addiction* (ahead of print, Sept 4, 2020). doi: 10.1111/add.15248
- Leone FT, Zhang Y, Evers-Casey S, et al: Initiating Pharmacologic Treatment in Tobacco-Dependent Adults: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2020; 202:e5–e31
- Rakofsky JJ, Talbot TB, Dunlop BW: A virtual standardized patient-based assessment tool to evaluate psychiatric residents' psychopharmacology proficiency. *Acad Psychiatry* 2020; 44:693–700

Reiff CM, Richman EE, Nemeroff CB, et al: Psychedelics and psychedelic-assisted psychotherapy. *Am J Psychiatry* 2020; 177:391–410

- Solmi M, Fornaro M, Ostinelli EG, et al: Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. *World Psychiatry* 2020; 19:214–232
- Yoshida K, Müller DJ: Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. *Mol Neuropsychiatry* 2020; 5(Suppl 1):1–26

2019

- Chang Z, Ghirardi L, Quinn PD, et al: Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. *Biol Psychiatry* 2019; 86:335–343
- Corponi F, Fabbri C, Bitter I, et al: Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur Neuropsychopharmacol* 2019; 29:971–985
- Earley W, Burgess MV, Rebeda L, et al: Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. *Am J Psychiatry* 2019; 176:439–448
- Factor SA, Burkhard PR, Caroff S, et al: Recent developments in drug-induced movement disorders: a mixed picture. *Lancet Neurol* 2019; 18:880–890
- Furukawa TA, Cipriani A, Cowen PJ, et al: Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry* 2019; 6:601–609
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet* 2019; 394:939–951
- Kingsberg SA, Clayton AH, Portman D, et al: Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. *Obstet Gynecol* 2019; 134:899–908

Pardis P, Remington G, Panda R, et al: Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. *J Psychopharmacol* 2019; 33:1187–1198

Vancampfort D, Firth J, Correll CU, et al: The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. *World Psychiatry* 2019; 18:53–66

Waxmonsky JG, Pelham WE III, Campa A, et al: A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. *J Am Acad Child Adolesc Psychiatry* 2020; 59:1330–1341

Wolraich ML, Hagan JF Jr, Allan C, et al: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics* 2019; 144:e20192528

2018

Clayton AH, Goldstein I, Kim NN, et al: The International Society for the Study of Women's Sexual Health process of care for management of hypoactive sexual desire disorder in women. *Mayo Clin Proc* 2018; 93:467–487

Cortese S, Adamo N, Del Giovane C, et al: Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2018; 5:727–738

Mentzel TQ, van der Snoek R, Lieveerse R, et al: Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. *J Clin Psychiatry* 2018; 79:17r11852

Solmi M, Pigato G, Kane JM, et al: Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. *Drug Des Devel Ther* 2018; 12:1215–1238

Walshaw PD, Gyulai L, Bauer M, et al: Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: a double-blind placebo-controlled trial of levothyroxine (L-T₄) and triiodothyronine (T₃). *Bipolar Disord* 2018; 20:594–603

FURTHER READING

Carbon M, Hsieh CH, Kane JM, et al: Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. *J Clin Psychiatry* 2017; 78:e264–e278

Fernandez HH, Factor SA, Hauser RA, et al: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. *Neurology* 2017; 88:2003–2010

Hauser RA, Factor SA, Marder SR, et al: KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. *Am J Psychiatry* 2017; 174:476–484

Kanes S, Colquhoun H, Gunduz-Bruce H, et al: Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. *Lancet* 2017; 390:480–489

Liu B, Zhang Y, Fang H, et al: Efficacy and safety of long-term antidepressant treatment for bipolar disorders: a meta-analysis of randomized controlled trials. *J Affect Disord* 2017; 223:41–48

McGirr A, Vöhringer PA, Ghaemi SN, et al: Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. *Lancet Psychiatry* 2016; 3:1138–1146